Clinical News

Clinical Status

<div class="articleContainer"><div class="articleWrapper"><div class="articleContent"><h1 class="text title">Veletri tezosentan: Phase III started</h1><div class="byline">WIR Staff</div><div class="date"></div></div></div></div>

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

ATLN said last half it began a double-blind, placebo-controlled, international Phase III trial. ......

Cardiovascular

Ophthalmic

Veletri tezosentan: Phase III started

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Distillery: Disruptive Innovation

Distillery

Hot Topics

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

Bio€quity Europe

BioCentury Grand Rounds 2024

BioCentury Grand Rounds

The BioCentury-BayHelix China Healthcare Summit

BioCentury-BayHelix China Healthcare Summit

The BioCentury Show

Webinars - Upcoming & On-Demand

Events

My Workspace

Company Overview

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Request a Trial

Request a Subscription

Advertising - Sponsorship Inquiry

Media Kit

Request BioCentury's BCIQ Brochure

Customer Resource Center

Career Opportunities

Contact

Home